Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;67(2):e28080.
doi: 10.1002/pbc.28080. Epub 2019 Nov 17.

Outcomes following proton therapy for Ewing sarcoma of the cranium and skull base

Shivam M Kharod  1 , Daniel J Indelicato  1 , Ronny L Rotondo  1 , Raymond B Mailhot Vega  1 , Haruka Uezono  1 , Christopher G Morris  1 , Scott Bradfield  2 , Eric S Sandler  2 , Julie A Bradley  1
Affiliations

Outcomes following proton therapy for Ewing sarcoma of the cranium and skull base

Shivam M Kharod et al. Pediatr Blood Cancer. 2020 Feb.

Abstract

Purpose: Despite the dosimetric advantages of proton therapy, little data exist on patients who receive proton therapy for Ewing sarcoma of the cranium and skull base. This study reports local disease control and toxicity in such patients.

Materials/methods: We reviewed 25 patients (≤21 years old) with nonmetastatic Ewing sarcoma of the cranium and skull base treated between 2008 and 2018. Treatment toxicity was graded per the Common Terminology Criteria for Adverse Events v4.0. The Kaplan-Meier product limit method provided estimates of disease control and survival.

Results: Median patient age was 5.9 years (range, 1-21.7). Tumor subsites included the skull base (48%), non-skull-base calvarial bones (28%), paranasal sinuses (20%), and nasal cavity (4%). All patients underwent multiagent alkylator- and anthracycline-based chemotherapy; 16% underwent gross total resection (GTR) before radiation. Clinical target volume (CTV) 1 received 45 GyRBE and CTV2 received 50.4 GyRBE following GTR or 54-55.8 GyRBE following biopsy or subtotal resection. Median follow-up was 3.7 years (range, 0.26-8.3); no patients were lost. The 4-year local control, disease-free survival, and overall survival rates were 96%, 86%, and 92%, respectively. Two patients experienced in-field recurrences. One patient experienced bilateral conductive hearing loss requiring aids, two patients developed intracranial vasculopathy, and 6 patients required hormone replacement therapy for neuroendocrine deficits. None developed a secondary malignancy.

Conclusion: Proton therapy is associated with a favorable therapeutic ratio in children with large Ewing tumors of the cranium and skull base. Despite its high conformality, we observed excellent local control and no marginal recurrences. Treatment dosimetry predicts limited long-term neurocognitive and neuroendocrine side effects.

Keywords: Ewing sarcoma; outcomes; proton therapy; radiotherapy; skull base; toxicity.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. National Cancer Institute. Ewing sarcoma treatment (PDQ®)-health professional version. 2018. https://www.cancer.gov/types/bone/hp/ewing-treatment-pdq. Accessed February 2, 2018.
    1. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol. 2008;20(4):412-418.
    1. Siegal GP, Oliver WR, Reinus WR, et al. Primary Ewing's sarcoma involving the bones of the head and neck. Cancer. 1987;60(11):2829-2840.
    1. Solomon LW, Frustino JL, Loree TR, et al. Ewing sarcoma of the mandibular condyle: multidisciplinary management optimizes outcome. Head Neck. 2008;30(3):405-410.
    1. Lockney NA, Friedman DN, Wexler LH, et al. Late toxicities of intensity-modulated radiation therapy for head and neck rhabdomyosarcoma. Pediatr Blood Cancer. 2016;63(9):1608-1614.

Publication types

MeSH terms